Image copyright Pfizer Image caption J.J.&J. booster was a new drug Pfizer developed in 1988
A new drug Pfizer developed in 1988 for men with prostate cancer is the new first in class treatment for the disease.
Called J.J.&J. Booster, the drug was approved by the European Medicines Agency in October for both men and women diagnosed with prostate cancer.
For this trial, researchers wanted to make sure the drug was safe and effective in a large study that included up to 45,000 men.
The study was published in the New England Journal of Medicine.
The study also looked at the risks and benefits of the drug over six months, and long-term.
There were no significant differences found between men who took J.J.&J. Booster and those who took placebo. The study found people who took booster had little to no evidence of prostate cancer.
J.J.&J. Booster is the first new first in class treatment for men with prostate cancer in 40 years, according to the study.
This drug does not use anything that was not previously approved.
Image copyright AFP Image caption There is currently no standard treatment for prostate cancer in which the patient gets to take a larger pill to help them live longer
It is slightly different to other first in class drugs, including Ibrance, the only other first in class prostate cancer treatment available in the UK and around the world.
In the UK, a man with stage 4 prostate cancer receives the drug, which costs £26,000 a year.
All over the world, over 20 million people in the UK alone receive prostate cancer treatment every year.
Statistically, very few people die of prostate cancer, which means millions of patients are being treated with time-wasting drugs.
Image copyright Mike Keisler Image caption J.J.&J. Booster targets tumours on the prostate gland to prevent and treat the disease. Image caption The drug is most effective when taken within 24 hours of initial diagnosis
Doctors in the UK would like to see surgery as a first line of treatment, but even men who have surgery, relapse quickly with a recurrence of their cancer, on average around once every eight months.
Although a tumour is removed, prostate cancer often returns.
This is why doctors are increasingly looking at new treatments that target the tumour that is causing the disease, or remove it with a needle and are more effective if patients receive the drug within 24 hours.
A trial of this treatment in a meningitis sufferer in the UK showed it caused an 80% lower death rate and had an 87% reduction in recurrence of the disease, compared to Ibrance.